221 related articles for article (PubMed ID: 30137742)
1. Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2.
Garibsingh RA; Otte NJ; Ndaru E; Colas C; Grewer C; Holst J; Schlessinger A
Front Chem; 2018; 6():279. PubMed ID: 30137742
[TBL] [Abstract][Full Text] [Related]
2. Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.
Colas C; Grewer C; Otte NJ; Gameiro A; Albers T; Singh K; Shere H; Bonomi M; Holst J; Schlessinger A
PLoS Comput Biol; 2015 Oct; 11(10):e1004477. PubMed ID: 26444490
[TBL] [Abstract][Full Text] [Related]
3. Conserved allosteric inhibition mechanism in SLC1 transporters.
Dong Y; Wang J; Garibsingh RA; Hutchinson K; Shi Y; Eisenberg G; Yu X; Schlessinger A; Grewer C
Elife; 2023 Mar; 12():. PubMed ID: 36856089
[TBL] [Abstract][Full Text] [Related]
4. Novel alanine serine cysteine transporter 2 (ASCT2) inhibitors based on sulfonamide and sulfonic acid ester scaffolds.
Ndaru E; Garibsingh RA; Shi Y; Wallace E; Zakrepine P; Wang J; Schlessinger A; Grewer C
J Gen Physiol; 2019 Mar; 151(3):357-368. PubMed ID: 30718375
[TBL] [Abstract][Full Text] [Related]
5. Structural characterisation reveals insights into substrate recognition by the glutamine transporter ASCT2/SLC1A5.
Scopelliti AJ; Font J; Vandenberg RJ; Boudker O; Ryan RM
Nat Commun; 2018 Jan; 9(1):38. PubMed ID: 29295993
[TBL] [Abstract][Full Text] [Related]
6. Rational design of ASCT2 inhibitors using an integrated experimental-computational approach.
Garibsingh RA; Ndaru E; Garaeva AA; Shi Y; Zielewicz L; Zakrepine P; Bonomi M; Slotboom DJ; Paulino C; Grewer C; Schlessinger A
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507995
[TBL] [Abstract][Full Text] [Related]
7. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes.
Gegelashvili M; Rodriguez-Kern A; Pirozhkova I; Zhang J; Sung L; Gegelashvili G
Neurochem Int; 2006; 48(6-7):611-5. PubMed ID: 16516348
[TBL] [Abstract][Full Text] [Related]
8. The Human SLC1A5 (ASCT2) Amino Acid Transporter: From Function to Structure and Role in Cell Biology.
Scalise M; Pochini L; Console L; Losso MA; Indiveri C
Front Cell Dev Biol; 2018; 6():96. PubMed ID: 30234109
[TBL] [Abstract][Full Text] [Related]
9. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
10. Cryo-EM structures of the human glutamine transporter SLC1A5 (ASCT2) in the outward-facing conformation.
Yu X; Plotnikova O; Bonin PD; Subashi TA; McLellan TJ; Dumlao D; Che Y; Dong YY; Carpenter EP; West GM; Qiu X; Culp JS; Han S
Elife; 2019 Oct; 8():. PubMed ID: 31580259
[TBL] [Abstract][Full Text] [Related]
11. Defining substrate and blocker activity of alanine-serine-cysteine transporter 2 (ASCT2) Ligands with Novel Serine Analogs.
Albers T; Marsiglia W; Thomas T; Gameiro A; Grewer C
Mol Pharmacol; 2012 Mar; 81(3):356-65. PubMed ID: 22113081
[TBL] [Abstract][Full Text] [Related]
12. Alanine serine cysteine transporter (ASCT) substrate binding site properties probed with hydroxyhomoserine esters.
Ndaru E; Zielewicz L; Shi Y; Hutchinson K; Garibsingh RA; Schlessinger A; Grewer C
J Phys Org Chem; 2022 Nov; 35(11):. PubMed ID: 36568026
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Synthesis of Hydroxy-l-Proline Blockers of the Neutral Amino Acid Transporters SLC1A4 (ASCT1) and SLC1A5 (ASCT2).
Lyda BR; Leary GP; Farnsworth J; Seaver B; Silvius D; Kavanaugh MP; Esslinger CS; Natale NR
Molecules; 2024 May; 29(10):. PubMed ID: 38792190
[TBL] [Abstract][Full Text] [Related]
14. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the neutral amino acid transporter ASCT2 with basic amino acids.
Ndaru E; Garibsingh RA; Zielewicz L; Schlessinger A; Grewer C
Biochem J; 2020 Apr; 477(8):1443-1457. PubMed ID: 32242892
[TBL] [Abstract][Full Text] [Related]
16. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
17. ASCT2 is the primary serine transporter in cancer cells.
Conger KO; Chidley C; Ozgurses ME; Zhao H; Kim Y; Semina SE; Burns P; Rawat V; Sheldon R; Ben-Sahra I; Frasor J; Sorger PK; DeNicola GM; Coloff JL
bioRxiv; 2023 Oct; ():. PubMed ID: 37873453
[TBL] [Abstract][Full Text] [Related]
18. Structure activity relationships of benzylproline-derived inhibitors of the glutamine transporter ASCT2.
Singh K; Tanui R; Gameiro A; Eisenberg G; Colas C; Schlessinger A; Grewer C
Bioorg Med Chem Lett; 2017 Feb; 27(3):398-402. PubMed ID: 28057420
[TBL] [Abstract][Full Text] [Related]
19. Cysteine is not a substrate but a specific modulator of human ASCT2 (SLC1A5) transporter.
Scalise M; Pochini L; Pingitore P; Hedfalk K; Indiveri C
FEBS Lett; 2015 Nov; 589(23):3617-23. PubMed ID: 26492990
[TBL] [Abstract][Full Text] [Related]
20. Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.
Bothwell PJ; Kron CD; Wittke EF; Czerniak BN; Bode BP
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30029480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
